Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Targeting Ovarian Carcinoma with TSP-1:CD47 Antagonist TAX2 Activates Anti-Tumor Immunity

Abstract : TAX2 peptide is a cyclic peptide that acts as an orthosteric antagonist for thrombospondin-1 (TSP-1) interaction with CD47. TAX2 was first described for its anti-angiogenic activities and showed anti-cancer efficacy in numerous preclinical models. Here, we aimed at providing an extensive molecular characterization of TAX2 mode of action, while evaluating its potential in ovarian cancer therapy. Multidisciplinary approaches were used to qualify a TAX2 drug candidate in terms of stability, solubility and potency. Then, efficacy studies, together with benchmark experiments, were performed in relevant mouse models of ovarian carcinoma. TAX2 peptide appears to be stable and soluble in clinically relevant solvents, while displaying a favorable safety profile. Moreover, clinical data mining allowed for the identification of TSP-1 as a relevant pharmacological target in ovarian cancer. In mice, TAX2 therapy inhibits ovarian tumor growth and metastatic dissemination, while activating anti-cancer adaptive immunity. Interestingly, TAX2 also synergizes when administered in combination with anti-PD-1 immune checkpoint inhibitiors. Altogether, our data expose TAX2 as an optimized candidate with advanced preclinical characterization. Using relevant syngeneic ovarian carcinoma models, we highlighted TAX2’s ability to convert poorly immunogenic tumors into ones displaying effective anti-tumor T-cell immunity.
Type de document :
Article dans une revue
Liste complète des métadonnées
Contributeur : Catherine Moali Connectez-vous pour contacter le contributeur
Soumis le : lundi 11 octobre 2021 - 10:34:33
Dernière modification le : jeudi 14 octobre 2021 - 13:10:09


Fichiers éditeurs autorisés sur une archive ouverte




Albin Jeanne, Thomas Sarazin, Magalie Charlé, Catherine Moali, Caroline Fichel, et al.. Targeting Ovarian Carcinoma with TSP-1:CD47 Antagonist TAX2 Activates Anti-Tumor Immunity. Cancers, MDPI, 2021, 13 (19), pp.5019. ⟨10.3390/cancers13195019⟩. ⟨hal-03372825⟩



Consultations de la notice


Téléchargements de fichiers